UK-based clinical AI technology company, Sensyne Health (SENS) , has named multinational corporation, Cognizant, and Agorai, a data infrastructure specialist, as its partners for the launch and sale of its digital health software products in the United States.
Initially, Sensyne will sell three software products managing a range of conditions, GDm-Health for gestational diabetes, EDGE for Chronic Obstructive Pulmonary Disease, and Support-HF, for heart failure.
“Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers,” commented Lord Paul Drayson, CEO of Sensyne Health.
GDm-Health, which will be the first to launch, is currently used by 15 NHS Trusts, helping over 6,100 patients in the UK manage and control gestational diabetes, which can lead to high blood pressure or premature birth.
All products were invented and developed in the UK’s NHS in collaboration with the University of Oxford, and then licensed to Sensyne Health.
The NHS and Sensyne will share financial returns under the agreements with Cognizant and Agorai via Sensyne’s unique partnership model.
"Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK's NHS, is realised in the US market,” Lord Drayson added.
Follow News & Updates from Sensyne Health: